Drug class
Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives
The phrase "Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives" is a compendial classification string rather than an official FDA Established Pharmacologic Class, representing lipid-regulating agents formulated from eicosapentaenoic acid. Read more about Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives
30 drugs in this class 26 manufacturers
Drugs in Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives
OMEGA-3 ACID ETHYL ESTERS
LOVAZA (omega-3 acid ethyl esters)
ICOSAPENT ETHYL
OMEGA-3 ACID ETHYL ESTERS
ICOSAPENT ETHYL
ICOSAPENT ETHYL
ICOSAPENT ETHYL
OMEGA-3 ACID ETHYL ESTERS
The phrase "Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives" is a compendial classification string rather than an official FDA Established Pharmacologic Class, representing lipid-regulating agents formulated from eicosapentaenoic acid.
These agents—most notably icosapent ethyl and omega-3 acid ethyl ester mixtures—primarily function by suppressing hepatic very-low-density lipoprotein and triglyceride synthesis while enhancing triglyceride clearance from circulating lipoproteins.
Therapeutically, they are used as an adjunct to dietary modification to treat severe hypertriglyceridemia and, in purified single-agent form, to lower cardiovascular event risk in select high-risk patients with elevated triglyceride levels.
-
fda.gov
The phrase "Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives" is a compendial classification string rather than an official FDA Established Pharmacologic Class, representing lipid-regulating agents formulated from eicosapentaenoic acid
-
medlineplus.gov
The phrase "Antihyperlipidemic-eicosapentaenoic acid (EPA) derivatives" is a compendial classification string rather than an official FDA Established Pharmacologic Class, representing lipid-regulating agents formulated from eicosapentaenoic acid
-
fda.gov
These agents—most notably icosapent ethyl and omega-3 acid ethyl ester mixtures—primarily function by suppressing hepatic very-low-density lipoprotein and triglyceride synthesis while enhancing triglyceride clearance from circulating lipoproteins
-
medlineplus.gov
These agents—most notably icosapent ethyl and omega-3 acid ethyl ester mixtures—primarily function by suppressing hepatic very-low-density lipoprotein and triglyceride synthesis while enhancing triglyceride clearance from circulating lipoproteins
-
fda.gov
Therapeutically, they are used as an adjunct to dietary modification to treat severe hypertriglyceridemia and, in purified single-agent form, to lower cardiovascular event risk in select high-risk patients with elevated triglyceride levels
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.